Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K.
Kondo K, et al. Among authors: estrov z.
Leukemia. 2018 Apr;32(4):960-970. doi: 10.1038/leu.2017.304. Epub 2017 Oct 3.
Leukemia. 2018.
PMID: 28972595
Free PMC article.